8-K: Nortech Systems Reports Q2 Growth Amidst EBITDA Dip

Nortech Systems announced second-quarter results with a 9.3% increase in net sales to $33.5 million, driven by strong backlog growth, though adjusted EBITDA saw a 12.6% decline.

Summary

• Nortech Systems reported second-quarter 2026 net sales of $33.5 million, a 9.3% increase from $30.7 million in the second quarter of 2025.
• Net income for Q2 2026 was $316 thousand, or $0.11 per basic share, a slight increase from $313 thousand, or $0.12 per basic share, in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $938 thousand, a decrease from $1.1 million in Q2 2025.
• The company's 90-day backlog grew to $33.4 million as of June 30, 2026, up from $26.6 million in the prior year.
• Total backlog increased by 20% year-over-year to $93.8 million as of June 30, 2026.
• Year-to-date net sales increased by 10.9% to $63.9 million, while year-to-date net income was $282 thousand, a significant improvement from a net loss of $1,003 thousand in the same period of 2025.
• Year-to-date Adjusted EBITDA was $1.3 million, a substantial increase from $73 thousand in the prior year, though Q2 EBITDA decreased.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, showing revenue growth and improved gross margins, but with a notable decrease in EBITDA and a significant drop in net income for the year-to-date period compared to the prior year.

Positives

• Net sales increased by 9.3% to $33.5 million in Q2 2026 compared to Q2 2025.
• Gross profit increased by 17.9% to $5.7 million in Q2 2026.
• Year-to-date net income improved significantly to $282 thousand from a net loss of $1,003 thousand in the prior year.
• Year-to-date Adjusted EBITDA saw a substantial increase to $1.3 million from $73 thousand in the prior year.
• The 90-day backlog increased to $33.4 million from $26.6 million year-over-year.
• Total backlog grew by 20% to $93.8 million year-over-year.
• Management highlights improved gross margins and positive operating income reflecting restructuring benefits.
• Customer interest in nearshoring and regional manufacturing strategies is noted as a positive positioning for Nortech.

Negatives

• Adjusted EBITDA decreased by 12.6% to $938 thousand in Q2 2026 compared to $1.1 million in Q2 2025.
• Net income per basic share slightly decreased to $0.11 in Q2 2026 from $0.12 in Q2 2025.
• Operating expenses increased by 24.1% in Q2 2026 compared to Q2 2025.
• Year-to-date net income per basic share was $0.10, a decrease from $0.12 in Q2 2026, and significantly down from $0.10 in YTD 2026 compared to a loss of $(0.36) in YTD 2025.
• Cash used in operating activities for the six months ended June 30, 2026, was $2.4 million, compared to $2.8 million used in the same period of 2025.

Risks

• Commodity cost increases coupled with challenges in raising prices and/or customer pressure to reduce prices.
• Supply chain disruptions leading to shortages of critical components.
• Volatility in market conditions which may affect demand for the Company's products.
• Increased competition and/or reduced demand.
• Changes in the reliability and efficiency of operating facilities or those of third parties.
• Risks related to the availability of labor.
• The unanticipated loss of any key member of senior management.
• Geopolitical, economic, financial and business conditions including changing tariff environment.

Future Outlook

Management remains focused on converting strong customer engagement into sustainable growth and long-term value, leveraging opportunities in attractive markets like Aerospace and Defense and Medical, and capitalizing on nearshoring and regional manufacturing trends. The company anticipates continued growth and long-term value creation.

Management Comments

• "Nortech delivered a solid second quarter, with year-over-year revenue growth, improved gross margins, and continued positive operating income reflecting the benefits of our restructuring actions and disciplined execution."
• "We are encouraged by the continued strength of our bookings and our backlog, which we view as an important leading indicator of future business prospects, including opportunities in attractive markets such as Aerospace and Defense as well as Medical."
• "We are also seeing continued customer interest in nearshoring and regional manufacturing strategies, where our North American footprint, combined with our China operations, positions Nortech well to support customers evolving supply chain needs."
• "As we move through the second half of 2026, we remain focused on converting strong customer engagement into sustainable growth and long-term value."

Industry Context

StockSavvy.ai notes that Nortech's focus on electromedical and electromechanical solutions for medical imaging, medical device, industrial, and aerospace & defense markets aligns with broader industry trends favoring specialized manufacturing and resilient supply chains. The emphasis on nearshoring and regionalization is a direct response to global supply chain challenges experienced across many manufacturing sectors.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and improved year-to-date profitability, though Q2 EBITDA decline may temper immediate sentiment.
• Employees: Continued focus on restructuring and disciplined execution may imply ongoing operational adjustments.
• Customers: Benefit from Nortech's positioning in nearshoring and regional manufacturing, potentially leading to more stable supply chains.
• Suppliers: Increased demand from backlog growth may lead to greater order volumes.

Next Steps

• Focus on converting strong customer engagement into sustainable growth and long-term value.
• Continue to leverage opportunities in attractive markets such as Aerospace and Defense as well as Medical.
• Support customers' evolving supply chain needs through North American and China operations, capitalizing on nearshoring and regional manufacturing strategies.
• Continue disciplined execution of restructuring actions.

Key Dates

Recommendation

The filing shows positive revenue growth and a strong improvement in year-to-date profitability, alongside a significant increase in backlog, which are positive indicators. However, the decrease in Q2 Adjusted EBITDA and a slight dip in Q2 EPS warrant caution. The company is executing on strategic initiatives like restructuring and nearshoring, but the mixed quarterly performance suggests a 'hold' position until sustained improvement in key profitability metrics like EBITDA is demonstrated.

Keywords

electromedical manufacturing, electromechanical solutions, medical device manufacturing, aerospace and defense, contract manufacturing, supply chain solutions, regional manufacturing, backlog growth